The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,062.00
Bid: 12,018.00
Ask: 12,022.00
Change: 38.00 (0.32%)
Spread: 4.00 (0.033%)
Open: 11,950.00
High: 12,142.00
Low: 11,944.00
Prev. Close: 12,024.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)-AstraZeneca Plc

22 May 2014 11:58

RNS Number : 8236H
JPMorgan Securities Plc
22 May 2014
 



FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

J.P. Morgan Securities plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

AstraZeneca Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Pfizer Inc.

(d) Date dealing undertaken:

21 May 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes

 

Pfizer Inc.

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Ordinary Shares

Purchases

 

 

Sales

1,872,379

47

 

3,245,770

44.5006 GBP

 481.6000 SEK

 

44.5050 GBP

42.9150 GBP

 481.6000 SEK

 

43.1350 GBP

 

 (b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(GBP)

Ordinary Shares

 

 

Equity Swap

 

 

Long

 

 

 

 

Short

 

 

43.5900

 44.1011

 44.1956

 43.1950

 

 43.6198

 43.6207

 43.6972

 43.7032

 43.7033

 43.7800

 43.8450

 43.8913

 43.9593

 43.9902

 481.6193

496,996

 4,720

 2,852

 1,713,398

 

2,604

 1,365

 12,545

 1,515

 13,949

 11

 767,404

 12

 167

 898

 47

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

(GBP)

Type

e.g. American, European etc.

Expiry date

 

Option money paid/ received per unit

(GBP)

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

(GBP)

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

Date of disclosure:

22 May 2014

Contact name:

Tung T Le

Telephone number:

020 7742 7272

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEREAESAASXLEFF
Date   Source Headline
23rd Sep 20217:00 amRNSNew Sustainability Committee of the Board
21st Sep 20217:00 amRNSAstraZeneca $360m Irish manufacturing investment
20th Sep 20217:00 amRNSEnhertu reduced risk of disease progression by 72%
9th Sep 20214:00 pmRNSImfinzi improves survival in NSCLC in POSEIDON
9th Sep 20217:00 amRNSPT027 PhIII asthma trials met primary endpoints
3rd Sep 20217:00 amRNSUltomiris approved in EU for children with PNH
1st Sep 20213:00 pmRNSTotal Voting Rights
26th Aug 20217:05 amRNSForxiga approved in Japan for CKD
26th Aug 20217:00 amRNSALXN1840 Wilson Phase III met primary endpoint
20th Aug 20217:05 amRNSUpdate on Ultomiris Phase III ALS trial
20th Aug 20217:00 amRNSAZD7442 prophylaxis trial met primary endpoint
16th Aug 20213:00 pmRNSDirector/PDMR Shareholding
11th Aug 20212:35 pmRNSUpdate on US review of roxadustat
9th Aug 20217:05 amRNSForxiga approved in the EU for CKD
9th Aug 20217:00 amRNSEnhertu head-to-head trial meets primary endpoint
2nd Aug 20213:00 pmRNSTotal Voting Rights
2nd Aug 20217:00 amRNSSaphnelo approved in the US for SLE
29th Jul 20217:00 amRNSAZN: H1 2021 Results
26th Jul 20217:00 amRNSUltomiris recommended in EU for children with PNH
22nd Jul 20217:00 amRNSDirectorate Change
21st Jul 20213:56 pmRNSDirector/PDMR Shareholding
21st Jul 20213:45 pmRNSTotal Voting Rights
21st Jul 20211:45 pmRNSAcquisition of Alexion completed
19th Jul 20217:00 amRNSImfinzi approved in China for extensive-stage SCLC
16th Jul 20217:00 amRNSStatus on US FDA Advisory Committee for roxadustat
15th Jul 20215:30 pmRNSAstraZeneca
14th Jul 20217:08 amRNSAstraZeneca-Alexion transaction cleared in the UK
8th Jul 20217:00 amRNSTezepelumab granted FDA Priority Review for asthma
6th Jul 20217:00 amRNSAstraZeneca-Alexion transaction cleared in the EU
1st Jul 20213:00 pmRNSTotal Voting Rights
28th Jun 20217:05 amRNSForxiga recommended in EU for patients with CKD
28th Jun 20217:00 amRNSNirsevimab PhII/III trial confirms safety profile
24th Jun 20217:00 amRNSLynparza approved in China for prostate cancer
23rd Jun 20217:00 amRNSOrpathys approved in China for lung cancer
22nd Jun 20217:00 amRNSKoselugo approved in the EU for children with NF1
15th Jun 20217:00 amRNSUpdate on AZD7442 STORM CHASER trial
10th Jun 202111:32 amRNSStabilisation Notice
7th Jun 20217:00 amRNSCalquence head-to-head results versus ibrutinib
4th Jun 20217:05 amRNSLynparza reduced recurrence risk in breast cancer
4th Jun 20217:00 amRNSAstraZeneca appoints new Chief Financial Officer
2nd Jun 20217:00 amRNSPublication of Final Terms
1st Jun 20213:01 pmRNSBlock listing Interim Review
1st Jun 20213:00 pmRNSTotal Voting Rights
28th May 20217:00 amRNSTagrisso approved in EU in early lung cancer
27th May 20214:41 pmRNSSecond Price Monitoring Extn
27th May 20214:36 pmRNSPrice Monitoring Extension
27th May 20217:00 amRNSAstraZeneca prices a EUR800m bond offering
26th May 20219:24 amRNSStabilisation Notice
26th May 20217:00 amRNSAstraZeneca prices a $7bn bond offering
25th May 20217:00 amRNSEMTN programme update - publication of Prospectus

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.